Robotic cystectomy

Who it suits

• Muscle-invasive bladder cancer (cT2 or higher) in patients fit for major pelvic surgery.
• High-risk non-muscle-invasive bladder cancer unresponsive to BCG.
• Selected recurrent or extensive carcinoma in situ where bladder-sparing treatment has failed.

What the operation involves

A robotic cystectomy has three conceptual stages:

1. Pelvic lymph node dissection - standard or extended, depending on risk.
2. Radical cystectomy - in men, removal of the bladder, prostate and seminal vesicles; in women, removal of the bladder, uterus (when applicable) and a cuff of vagina.
3. Urinary diversion - reconstruction of a new way for urine to leave the body. Options are discussed in detail pre-operatively:
   • Ileal conduit - a short segment of small bowel is used as a pipe that drains urine to a small opening on the abdominal wall (stoma) with an external bag. The most commonly chosen option.
   • Orthotopic neobladder - a new bladder is fashioned from a longer segment of small bowel and connected to the urethra, so the patient voids more or less normally. Requires good urethral function and motivated follow-up.
   • Continent cutaneous diversion - rarely used; a continent pouch with a catheterisable stoma.

Where intracorporeal reconstruction is performed, the entire operation is completed inside the abdomen without a large open incision; this is where robotic access has the clearest incremental benefit over extracorporeal techniques.

Hospital stay

Typical hospital stay is 7-10 nights, often with an enhanced recovery pathway that focuses on early feeding, early mobilisation and early catheter management. Full recovery takes several months.

Expected outcomes

• Oncologic control is comparable to open cystectomy in contemporary randomised and large observational series.⁴
• Intra-operative blood loss and transfusion requirement are lower with robotic access than with open surgery.
• Overall length of stay is broadly similar; the operation itself takes longer robotically.
• Long-term functional outcomes (continence for neobladder, stomal care for ileal conduit, kidney function, bowel function) depend more on the diversion type and patient factors than the surgical platform.

Potential complications

• Anastomotic or uretero-enteric leak from the reconstructed urinary tract.
• Bowel ileus or small-bowel obstruction, sometimes requiring re-intervention.
• Urinary tract infection and, occasionally, sepsis.
• Wound issues at the specimen extraction site.
• Longer-term metabolic effects of using bowel in the urinary tract.
• Sexual dysfunction and menopausal symptoms (in women) - discussed in detail pre-operatively.
• Cancer recurrence - monitored lifelong with imaging and cytology.

Alternatives

• Bladder-sparing trimodal therapy - maximal transurethral resection, chemotherapy and radiotherapy, in selected patients.
• Open radical cystectomy - still the most common approach worldwide.
• Systemic therapy alone - for metastatic disease or patients unfit for surgery.
• Palliative care pathways where surgery is not appropriate.

Resources